Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Technology, Consumer Services and Consumer Goods sectors led shares higher while losses in the...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Utilities, Consumer Services and Telecoms sectors led shares higher. At the close in NYSE, the...
Companies with non-deal roadshows or company visits/marketing with sell-side today:Taysha Gene Therapies (NASDAQ:TSHA) Annual Stockholder MeetingOmeros (NASDAQ:OMER) Annual...
Commercial-stage biopharmaceutical Omeros (NASDAQ:OMER) Corporation OMER announced encouraging preliminary results from an early-stage study of its MASP-3 inhibitor, OMS906.The...
Dates and content of the Prescription Drug User Fee Act are essential for portfolio managers of health-care stocks. A single positive or negative announcement from the U.S. Food...
PDUFA dates and content are essential for portfolio managers of healthcare stocks. A single positive or negative announcement from the US Food and Drug Administration (FDA) can...
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome, and COVID-19. OMS906, its inhibitor of MASP-3, an activator of the alternative pathway of complement, is initiating a Phase I b clinical program in paroxysmal nocturnal hemoglobinuria (PNH).
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Buy | Strong Buy | Sell |
| Technical Indicators | Strong Sell | Neutral | Sell | Strong Buy | Strong Sell |
| Summary | Strong Sell | Neutral | Neutral | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.37 | 8.47 | 8.16 | +0.24 | +2.95% | 6.64M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.205 | 1.23 | 1.19 | -0.0050 | -0.41% | 2.57M | NYSE | |||
| 3.60 | 3.65 | 3.54 | +0.080 | +2.27% | 10.10M | NYSE | |||
| 46.26 | 46.28 | 45.16 | +1.36 | +3.03% | 1.89M | NYSE | |||
| 1.085 | 1.10 | 1.01 | +0.0650 | +6.37% | 306.83K | NYSE | |||
| 32.74 | 32.75 | 31.69 | +0.89 | +2.81% | 4.93M | NYSE | |||
| 99.11 | 99.58 | 98.68 | +0.63 | +0.64% | 1.95M | NYSE | |||
| 58.71 | 58.72 | 57.73 | +1.20 | +2.09% | 618.32K | NYSE | |||
| 43.51 | 43.66 | 43.24 | -0.11 | -0.25% | 5.55M | NYSE | |||
| 50.90 | 51.04 | 49.74 | -0.20 | -0.39% | 3.16M | NYSE | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 128.20 | 128.52 | 126.71 | +1.21 | +0.95% | 768.09K | NYSE | |||
| 81.24 | 81.24 | 80.44 | +0.54 | +0.67% | 1.27M | NYSE | |||
| 50.11 | 50.39 | 48.55 | +1.82 | +3.77% | 25.57M | NYSE |